Drug Trial Radar · NCT04302064
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants
Last checked: Nov 20, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Apr 23, 2020
Primary completion
Sep 10, 2020
Study completion Sep 10, 2020
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Mar 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of single and potentially multiple doses of Eplontersen administered subcutaneously (SC) to healthy Japanese participants.
Conditions
- Healthy Participants
Interventions
EplontersenDrug
Eplontersen administered SC
PlaceboDrug
Eplontersen-matching placebo administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by SeverityTime frame: Up to 92 days
- Percentage of Participants with TEAEs Potentially Related to Study DrugTime frame: Up to 92 days
- Percentage of Participants with Changes in Clinically Significant (CS) Laboratory Value AbnormalitiesTime frame: Up to 92 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WCCT Global
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.